^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    etoposide IV

    i
    Other names: VP-16, BMY 40481, BMY-40481
    Company:
    Generic mfg.
    Drug class:
    Topoisomerase II inhibitor
    Related drugs:
    23h
    Circumvention of Topoisomerase IIα Intron 19 Intronic Polyadenylation (IPA) in Acquired Etoposide Resistant Human Leukemia K562 Cells. (PubMed, Mol Pharmacol)
    An antisense morpholino oligonucleotide (AMO) targeting the PAS also partially circumvented resistance. Results demonstrate the importance of intronic polyadenylation (IPA) in acquired drug resistance and points to tractable strategies to overcome this form of resistance to TOP2-targeted agents.
    Journal
    |
    TOP2A (DNA topoisomerase 2-alpha)
    |
    etoposide IV
    23h
    Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=38, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2023 --> Dec 2027 | Trial primary completion date: Dec 2023 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • etoposide IV
    23h
    Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma (clinicaltrials.gov)
    P1, N=93, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2024 --> Jun 2027 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • temozolomide • cytarabine • etoposide IV • pegylated liposomal doxorubicin
    23h
    A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, National Cancer Institute (NCI)
    New P2 trial
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    UGT1A1*28 • UGT1A1*1*1 • UGT1A1*28 + UGT1A1*6
    |
    cisplatin • etoposide IV • Beleodaq (belinostat)
    2d
    RATHL: Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma (clinicaltrials.gov)
    P3, N=1202, Completed, University College, London | Active, not recruiting --> Completed | Trial completion date: May 2023 --> May 2024
    Trial completion • Trial completion date • FDG PET • Metastases
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • dacarbazine • Matulane (procarbazine hydrochloride) • bleomycin • vinblastine • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    2d
    Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States. (PubMed, Clin Lymphoma Myeloma Leuk)
    Our findings support the use of PD-1 blockade in HIV-cHL for the same indications as the general population with cHL.
    Clinical • Journal • Real-world evidence • Real-world
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • carboplatin • ifosfamide • etoposide IV • Adcetris (brentuximab vedotin)
    3d
    Design, synthesis, in-silico studies and apoptotic activity of novel amide enriched 2-(1H)- quinazolinone derivatives. (PubMed, Heliyon)
    When compared to etoposide, every synthetic test compound (7a-j) exhibited moderate to excellent activity...Additionally, DFT investigations and MD simulations validated the predictions of molecular docking. According to the findings of the ADME analysis, oral absorption by humans is anticipated to be higher than 85 % for all test compounds.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    etoposide IV
    4d
    A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) (clinicaltrials.gov)
    P3, N=1656, Not yet recruiting, Children's Oncology Group
    New P3 trial
    |
    carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • irinotecan • vincristine • daunorubicin • dactinomycin
    7d
    A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Novartis Pharmaceuticals | N=39 --> 200
    Enrollment change • Combination therapy
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Lutathera (lutetium Lu 177 dotatate)
    8d
    DFCI 16-001: Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents (clinicaltrials.gov)
    P3, N=560, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Nov 2028 --> Nov 2034
    Trial completion date
    |
    dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • leucovorin calcium • Oncaspar liquid (pegaspargase) • nelarabine • mercaptopurine • dexrazoxane
    9d
    FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Centre Leon Berard
    New P2 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • RB1 (RB Transcriptional Corepressor 1)
    |
    PD-L1 expression • RB1 mutation
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • etoposide IV
    9d
    Chidamide+Decitabine Plus Anti-PD-1 Antibody in PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma. (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Chinese PLA General Hospital
    New P2 trial • IO biomarker
    |
    PD-1 (Programmed cell death 1)
    |
    carboplatin • gemcitabine • ifosfamide • etoposide IV • decitabine • pegylated liposomal doxorubicin • Adcetris (brentuximab vedotin) • Epidaza (chidamide)
    10d
    Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (clinicaltrials.gov)
    P3, N=478, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
    Enrollment open • Surgery
    |
    ALK (Anaplastic lymphoma kinase) • TERT (Telomerase Reverse Transcriptase) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    cisplatin • carboplatin • temozolomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • irinotecan • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • dexrazoxane
    10d
    Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma (clinicaltrials.gov)
    P2, N=137, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Mar 2024
    Trial completion • Trial completion date • Combination therapy
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    |
    Xalkori (crizotinib) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • Adcetris (brentuximab vedotin) • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
    12d
    Role of Protein Tyrosine Phosphatase Receptor Type E (PTPRE) in Chemoresistant Retinoblastoma. (PubMed, Int J Mol Sci)
    Etoposide-resistant RB cell lines and RB patients display significant higher PTPRE expression levels compared to chemosensitive counterparts and the healthy human retina, respectively...Additionally, PTPRE KD led to altered phosphorylation of protein kinase SGK3 and-dependent on the cell line-AKT and ERK1/2, suggesting potential PTPRE downstream signaling pathways. In summary, these results indicate an oncogenic role of PTPRE in chemoresistant retinoblastoma.
    Journal
    |
    MIR31 (MicroRNA 31)
    |
    etoposide IV
    13d
    TNIK inhibition sensitizes TNIK-overexpressing lung squamous cell carcinoma to radiotherapy. (PubMed, Mol Cancer Ther)
    The combination of NCB-0846 with cisplatin or etoposide was at best additive. In a subcutaneous xenograft in vivo model, pretreatment with NCB-0846 significantly enhanced the efficacy of IR and caused elevated necrosis in TNIKhigh LK2 tumors but not TNIKlow KNS62 tumors. Overall, these results indicate that TNIK inhibition may be a promising strategy to increase the efficacy of radiotherapy in LSCC patients with high TNIK expression.
    Journal • IO biomarker
    |
    TNIK (TRAF2 And NCK Interacting Kinase)
    |
    TNIK overexpression
    |
    cisplatin • etoposide IV • NCB-0846
    14d
    PROTAC EZH2 degrader-1 overcomes the resistance of podophyllotoxin derivatives in refractory small cell lung cancer with leptomeningeal metastasis. (PubMed, BMC Cancer)
    The SCLC-LM model effectively simulates the pathophysiological process of SCLC metastasis to the leptomeninges. PROTAC EZH2 degrader-1 overcomes chemoresistance in SCLC, suggesting its potential therapeutic value for SCLC LM.
    Journal
    |
    SLC44A4 (Solute Carrier Family 44 Member 4) • SLC4A4 (Solute carrier family 4 member 4) • DERL1 (Derlin 1)
    |
    cisplatin • etoposide IV • Vumon (teniposide)
    14d
    Glo-BNHL: A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2/3, N=210, Not yet recruiting, University of Birmingham | Trial completion date: Oct 2032 --> May 2033 | Initiation date: Oct 2023 --> May 2024 | Trial primary completion date: Oct 2030 --> May 2031
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    carboplatin • Rituxan (rituximab) • ifosfamide • etoposide IV • dexamethasone • Zynlonta (loncastuximab tesirine-lpyl) • odronextamab (REGN1979)
    15d
    Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma (clinicaltrials.gov)
    P1, N=50, Suspended, University of Washington | Recruiting --> Suspended
    Trial suspension
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL6 translocation
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • daunorubicin • Polivy (polatuzumab vedotin-piiq) • Neupogen (filgrastim)
    17d
    Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=41, Completed, Massachusetts General Hospital | Active, not recruiting --> Completed
    Trial completion
    |
    lenalidomide • cytarabine • etoposide IV • mitoxantrone • Depocyte (liposomal cytarabine)
    17d
    Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System (clinicaltrials.gov)
    P3, N=70, Completed, Children's Oncology Group | Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Mar 2024
    Trial completion • Trial completion date • Surgery
    |
    cisplatin • carboplatin • cyclophosphamide • etoposide IV • vincristine • leucovorin calcium • thiotepa • Neupogen (filgrastim) • methotrexate IV
    18d
    A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=90, Active, not recruiting, Celgene | Phase classification: P1b --> P1 | Trial completion date: Feb 2024 --> Jun 2024 | Trial primary completion date: Feb 2024 --> Jun 2024
    Phase classification • Trial completion date • Trial primary completion date • Combination therapy
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • etoposide IV • pulrodemstat (CC-90011)
    18d
    MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, Masonic Cancer Center, University of Minnesota
    New P2 trial
    |
    Keytruda (pembrolizumab) • cytarabine • etoposide IV • carmustine • melphalan
    21d
    Effect of Hepatic Impairment on Trilaciclib Pharmacokinetics. (PubMed, J Clin Pharmacol)
    Trilaciclib is a first-in-class, intravenous cyclin-dependent kinase 4 and 6 inhibitor approved for reducing the incidence of chemotherapy-induced myelosuppression in adult patients with extensive-stage small cell lung cancer receiving a platinum/etoposide-containing or topotecan-containing regimen. Ad hoc analysis using National Cancer Institute classification showed similar results. The US Food and Drug Administration-approved trilaciclib dose of 240 mg/m2 should be reduced by ∼30%, to 170 mg/m2, for patients with moderate or severe HI.
    PK/PD data • Journal
    |
    CDK4 (Cyclin-dependent kinase 4)
    |
    etoposide IV • topotecan • Cosela (trilaciclib)
    21d
    NeoSCLC-001: PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Beijing Chest Hospital, Capital Medical University
    New P2 trial
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab) • etoposide IV
    21d
    Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors (clinicaltrials.gov)
    P2, N=262, Active, not recruiting, Children's Oncology Group | Trial completion date: Mar 2024 --> Jun 2024 | Trial primary completion date: Mar 2024 --> Jun 2024
    Trial completion date • Trial primary completion date
    |
    AFP (Alpha-fetoprotein)
    |
    carboplatin • cyclophosphamide • ifosfamide • etoposide IV
    21d
    Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, Rachel Sanborn | Trial completion date: Nov 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Jun 2023
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • pemetrexed • etoposide IV
    22d
    Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001) (clinicaltrials.gov)
    P1, N=492, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Oct 2024 --> Aug 2024 | Trial primary completion date: Oct 2024 --> Aug 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • etoposide IV • vibostolimab (MK-7684) • vibostolimab/pembrolizumab (MK-7684A)
    22d
    OS2006: Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma (clinicaltrials.gov)
    P3, N=318, Active, not recruiting, UNICANCER | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    cisplatin • doxorubicin hydrochloride • ifosfamide • etoposide IV • zoledronic acid
    22d
    Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy (clinicaltrials.gov)
    P2, N=16, Active, not recruiting, Robert Redner, MD | Completed --> Active, not recruiting | Trial completion date: Feb 2023 --> Dec 2028
    Enrollment closed • Trial completion date
    |
    CD33 (CD33 Molecule)
    |
    CD33 expression
    |
    etoposide IV • Mylotarg (gemtuzumab ozogamicin) • mitoxantrone
    22d
    Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. (clinicaltrials.gov)
    P1/2, N=93, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
    New P1/2 trial • Combination therapy • Metastases
    |
    cisplatin • etoposide IV • ZG005
    23d
    NCI-2018-03732: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov)
    P2, N=42, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Sep 2024
    Trial completion date
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • IL6 (Interleukin 6) • CXCL9 (Chemokine (C-X-C motif) ligand 9)
    |
    MYCN amplification • IL6 expression
    |
    cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim) • dexrazoxane
    23d
    Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma (clinicaltrials.gov)
    P2, N=71, Active, not recruiting, The Hospital for Sick Children | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date
    |
    carboplatin • etoposide IV • vincristine • Neupogen (filgrastim)
    23d
    ALL Adult Consortium Trial: Adult ALL Trial (clinicaltrials.gov)
    P2, N=112, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date
    |
    imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine
    23d
    Study of Low-Dose Radiotherapy Concurrent Cisplatin/Carboplatin Plus Etoposide With Serplulimab for Patients With ES-SCLC (clinicaltrials.gov)
    P2, N=61, Recruiting, Sichuan University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • carboplatin • etoposide IV • Hansizhuang (serplulimab)
    24d
    Chemotherapy Followed by Response-Based Reduced Radiation Therapy for Patients With Central Nervous System Germinomas (clinicaltrials.gov)
    P2, N=240, Not yet recruiting, Children's Oncology Group
    New P2 trial
    |
    carboplatin • etoposide IV
    24d
    Comprehensive analysis of exosome gene LYPD3 and prognosis/immune cell infiltration in lung cancer. (PubMed, Transl Cancer Res)
    Additionally, the median half maximal inhibitory concentration (IC50) of bexarotene, cyclopamine, etoposide, and paclitaxel in LYPD3 high group was significantly lower than that in LYPD3 low group. LYPD3 is involved in many BPs of LC, such as regulating immune cell infiltration and affecting prognosis. Therefore, LYPD3 may have potential value as a biomarker for prognosis and immunotherapy in LC.
    Journal • IO biomarker • Immune cell
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • LYPD3 (LY6/PLAUR Domain Containing 3)
    |
    LYPD3 expression
    |
    paclitaxel • etoposide IV • Targretin oral (bexarotene oral) • cyclopamine
    25d
    A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab (clinicaltrials.gov)
    P1/2, N=39, Recruiting, Novartis Pharmaceuticals | Phase classification: P1 --> P1/2
    Phase classification • Combination therapy
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Lutathera (lutetium Lu 177 dotatate)
    27d
    Role of plasma EBV-DNA load and EBER status on newly diagnosed peripheral T-cell lymphoma. (PubMed, J Cancer Res Clin Oncol)
    EBER, DNA1, and DNA4 emerged as sensitive markers for prognosis. CHOP plus azacytidine might present a preferable option for PTCL patients with DNA methylation due to EBV infection.
    Journal
    |
    DNMT3A (DNA methyltransferase 1) • TET2 (Tet Methylcytosine Dioxygenase 2)
    |
    TET2 mutation
    |
    doxorubicin hydrochloride • azacitidine • cyclophosphamide • etoposide IV • vincristine • prednisone
    28d
    A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) (clinicaltrials.gov)
    P1/2, N=149, Not yet recruiting, Daiichi Sankyo
    New P1/2 trial • Combination therapy
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • ifinatamab deruxtecan (DS-7300)
    28d
    Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease. (PubMed, J Clin Oncol)
    The intensification of induction therapy with risk stratification on the basis of response to induction and hSCT for high-risk patients led to improved outcomes. Mitoxantrone had a superior anti-leukemic effect than liposomal daunorubicin.
    Journal
    |
    NPM1 (Nucleophosmin 1)
    |
    FLT3 wild-type
    |
    etoposide IV • mitoxantrone
    29d
    TOUCH: A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=97, Recruiting, Antengene Corporation | Trial primary completion date: Dec 2023 --> May 2024
    Trial primary completion date
    |
    carboplatin • gemcitabine • Tevimbra (tislelizumab) • ifosfamide • oxaliplatin • etoposide IV • Xpovio (selinexor)